Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brendan M Everett

Showing results (1-10 of 125) with videos related to

Pageof 13
Sort By:
Journal of the American College of Cardiology|February 4, 2017
Low-Density Lipoprotein Cholesterol and the On-Target Effects of Therapy: How Low Is Too Low?Brendan M Everett
Journal of the American College of Cardiology|May 18, 2019
Residual Inflammatory Risk: A Common and Important Risk Factor for Recurrent Cardiovascular EventsBrendan M Everett
Circulation|March 18, 2024
The Confusing Landscape of Cardiovascular Health Assessment, Promotion, and PredictionBrendan M Everett
Annals of Internal Medicine|May 19, 2010
Markers of mineral metabolism and cardiovascular diseaseBrendan M Everett
Trends in Cardiovascular Medicine|July 17, 2016
Cardiac troponin as a novel tool for cardiovascular risk prediction in ambulatory populationsBrendan M Everett
Heart (British Cardiac Society)|November 12, 2017
Cardiac troponin: the next tool for cardiovascular disease prevention in ambulatory patients?Brendan M Everett
Clinical Chemistry|April 3, 2010
B-type natriuretic peptides and the promise of improved cardiovascular risk predictionBrendan M Everett
Arteriosclerosis, Thrombosis, and Vascular Biology|March 1, 2019
Novel Antiatherosclerotic TherapiesPeter Libby, Brendan M Everett
Circulation|May 23, 2007
Letter by Ridker and Everett regarding article, "The inflammatory hypothesis: any progress in risk stratification and therapeutic targets?"Paul M Ridker, Brendan M Everett
Circulation|September 8, 2016
Finding Efficacy in a Safety Trial: Empagliflozin and Cardiovascular DeathBrendan M Everett, William R Hiatt
Pageof 13

Showing results (1-10 of 125) with videos related to

Sort By:
Pageof 13
Journal of the American College of Cardiology|February 4, 2017
Low-Density Lipoprotein Cholesterol and the On-Target Effects of Therapy: How Low Is Too Low?Brendan M Everett
Journal of the American College of Cardiology|May 18, 2019
Residual Inflammatory Risk: A Common and Important Risk Factor for Recurrent Cardiovascular EventsBrendan M Everett
Circulation|March 18, 2024
The Confusing Landscape of Cardiovascular Health Assessment, Promotion, and PredictionBrendan M Everett
Annals of Internal Medicine|May 19, 2010
Markers of mineral metabolism and cardiovascular diseaseBrendan M Everett
Trends in Cardiovascular Medicine|July 17, 2016
Cardiac troponin as a novel tool for cardiovascular risk prediction in ambulatory populationsBrendan M Everett
Heart (British Cardiac Society)|November 12, 2017
Cardiac troponin: the next tool for cardiovascular disease prevention in ambulatory patients?Brendan M Everett
Clinical Chemistry|April 3, 2010
B-type natriuretic peptides and the promise of improved cardiovascular risk predictionBrendan M Everett
Arteriosclerosis, Thrombosis, and Vascular Biology|March 1, 2019
Novel Antiatherosclerotic TherapiesPeter Libby, Brendan M Everett
Circulation|May 23, 2007
Letter by Ridker and Everett regarding article, "The inflammatory hypothesis: any progress in risk stratification and therapeutic targets?"Paul M Ridker, Brendan M Everett
Circulation|September 8, 2016
Finding Efficacy in a Safety Trial: Empagliflozin and Cardiovascular DeathBrendan M Everett, William R Hiatt
Pageof 13